156 related articles for article (PubMed ID: 29044862)
1. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck.
Hong MH; Kim CG; Koh YW; Choi EC; Kim J; Yoon SO; Kim HR; Cho BC
Head Neck; 2018 Jan; 40(1):55-62. PubMed ID: 29044862
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.
Airoldi M; Pedani F; Succo G; Gabriele AM; Ragona R; Marchionatti S; Bumma C
Cancer; 2001 Feb; 91(3):541-7. PubMed ID: 11169936
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases.
Airoldi M; Garzaro M; Pedani F; Ostellino O; Succo G; Riva G; Sensini M; Naqe N; Bellini E; Raimondo L; Pecorari G
Am J Clin Oncol; 2017 Feb; 40(1):86-90. PubMed ID: 25089531
[TBL] [Abstract][Full Text] [Related]
4. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Espinosa E; Zamora P; Millá A; Morales S; Molina R; Mira M; González Barón M;
Head Neck; 2002 Dec; 24(12):1054-9. PubMed ID: 12454943
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.
Conroy T; Etienne PL; Adenis A; Ducreux M; Paillot B; Oliveira J; Seitz JF; Francois E; Van Cutsem E; Wagener DJ; Kohser F; Daamen S; Praet M; Gorlia T; Baron B; Wils J;
Ann Oncol; 2002 May; 13(5):721-9. PubMed ID: 12075740
[TBL] [Abstract][Full Text] [Related]
7. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
[TBL] [Abstract][Full Text] [Related]
8. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen.
Gebbia V; Testa A; Borsellino N; Ferrera P; Tirrito M; Palmeri S
Ann Oncol; 2001 Jun; 12(6):767-72. PubMed ID: 11484950
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer.
Mustacchi G; Muggia M; Milani S; Ceccherini R; Leita ML; Dellach C
Ann Oncol; 2002 Nov; 13(11):1730-6. PubMed ID: 12419744
[TBL] [Abstract][Full Text] [Related]
11. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
[TBL] [Abstract][Full Text] [Related]
12. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck.
Gebbia V; Testa A; Di Gregorio C; Ingria F; Valenza R; Cannata G; Moschella F; Restivo G; Gebbia N
Am J Clin Oncol; 1995 Aug; 18(4):293-6. PubMed ID: 7625368
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.
Gedlicka C; Schüll B; Formanek M; Kornfehl J; Burian M; Knerer B; Selzer E; Scheithauer W; Kornek GV
Anticancer Drugs; 2002 Jun; 13(5):491-5. PubMed ID: 12045460
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
Yasuda H; Yamaya M; Nakayama K; Sasaki T; Ebihara S; Kanda A; Asada M; Inoue D; Suzuki T; Okazaki T; Takahashi H; Yoshida M; Kaneta T; Ishizawa K; Yamanda S; Tomita N; Yamasaki M; Kikuchi A; Kubo H; Sasaki H
J Clin Oncol; 2006 Feb; 24(4):688-94. PubMed ID: 16446342
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
